Table 2.

Identity of proteins in 2-DE gel with increased or decreased intensity after onset of cGVHD

Accession No.	Spot No.	MW (KDa)	pl	Identified protein	(VI)/× 105*	(VI) Fold change
P00738	489	46	4.8	haptoglobin-β	53.4	+4.2
	513	46	5.1	haptoglobin-β	47.1	+7.3
	522	45	5.2	haptoglobin-β	22.4	+6.5
	528	45	5.4	haptoglobin-β	6.5	+8.4
	552	40	5.6	haptoglobin-β	newly appeared
	661	21	5.6	haptoglobin-α	22.8	+37.1
	663	21	5.9	haptoglobin-α	12.3	+32.0
	664	21	5.3	haptoglobin-α	7.4	+35.2
P06727	488	47	4.8	apolipoprotein A-IV	60.2	+25.5
	489	46	4.8	apolipoprotein A-IV	53.4	+4.2
	491	48	4.7	apolipoprotein A-IV	21.0	+15.0
P01009	489	46	4.8	α-1-antitrypsin	53.4	+4.2
	513	46	5.1	α-1-antitrypsin	47.1	+7.3
	528	45	5.4	α-1-antitrypsin	16.5	+8.4
P27169	488	47	4.8	serum paraoxonase	60.2	+25.5
	491	48	4.7	serum paraoxonase	21.0	+15.0
P25311	488	47	4.8	Zn-α-2-glycoprotein	50.2	+25.5
	491	48	4.7	Zn-α-2-glycoprotein	21.0	+15.5
P04278	492	48	5.1	sex hormone-binding globulin	1.2	-5.1
P10909	537	39	4.8	clusterin precursor	0.6	-4.5
	547	38	4.9	clusterin precursor	0.5	-4.9
	556	36	4.8	clusterin precursor	absence
	726	13	5.6	clusterin precursor	0.1	-4.5
P02735	726	13	5.6	serum amyloid A protein precursor	0.1	-4.5
P02787	416	29	6.6	serotransferrin	absence
P01023	556	36	4.8	α-2-microglobulin	0.2	-7.5
P01028	526	31	6.6	complement C4	absence

Acession #: Number as listed in online protein database; VI: volume index